Abstract
Cortex and caudate specimens from human, non-human primate and rodent brains were examined for their ability to deaminate dopamine and for their sensitivity to irreversible monoamine oxidase (MAO) inhibitors. Using inhibition curves obtained with clorgyline, deprenyl and pargyline to estimate the relative proportions of MAO-A and MAO-B activity, dopamine was found to be deaminated predominantly by MAO-A in rat cortex and caudate. In contrast, dopamine was primarily an MAO-B substrate in human and vervet cortex and caudate. When clorgyline inhibition curves with tyramine or dopamine as substrate were compared in human, vervet and rat cortex, more pronounced species differences were found with dopamine than with tyramine. In all three species caudate tended to be more sensitive to inhibition by low concentrations of clorgyline than was cortex, suggesting a higher proportion of MAO-A activity in caudate. Similar species differences were also found when MAO-A activities were estimated using serotonin (5-HT): β-phenylethylamine (PEA) ratios (5-HT/5-HT + PEA). These ratios with selective substrates were highly correlated with clorgyline inhibition curves obtained with tyramine as substrate across 29 brain regions and tissues from different rodent and primate species (r=0.85, P<0.001). Data from both the substrate ratios and the clorgyline inhibition curves confirmed the relative predominance of MAO-B activity in primate brain regions (70–85%) as compared to rat brain regions (45%). Smaller species differences were observed in liver. Species differences in the proportion of brain MAO-A and B activities and in the deamination of dopamine and other substrates for MAO may have important implications in regard to the widespread use of rodent rather than primate models in the study of biogenic amine metabolism and of drugs affecting amine function.
Similar content being viewed by others
References
Birkmayer W, Riederer P, Youdim MBH, Linauer W (1975) The potentiation of the anti akinetic effect after l-Dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transmission 36:303–326
Braestrup C, Andersen H, Randrup A (1975) The monoamine oxidase B inhibitor deprenyl potentiates phenylethylamine behaviour in rats without inhibition of catecholamine metabolite formation. Eur J Pharmacol 34:181–187
Campbell IC, Robinson DS, Lovenberg W, Murphy DL (1979) The effects of chronic regimens of clorgyline and pargyline on monoamine metabolism in the rat brain. J Neurochem 32:49–55
Cross AJ, Glover V, Lofthouse R, Owen F (1978) Some observations on human brain monoamine oxidase. Proc of the B.P.S. Br J Pharmacol 63(3):408
Demarest KT, Azzaro AJ (1979) The association of type A monoamine oxidase with the nigrostriatal dopamine neuron. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 423–430
Donnelly CH, Murphy DL (1977) Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem Pharmacol 26:853–858
Donnelly CH, Richelson E, Murphy DL (1976) Properties of monoamine oxidase in mouse neuroblastoma N1E-115 cells. Biochem Pharmacol 25:1639–1643
Edwards DJ, Malsbury CW (1978) Characteristics of monoamine oxidases in brain and other organs of the golden hamster. Biochem Pharmacol 27:959–963
Fowler CJ, Callingham BA, Mantle TJ, Tipton KF (1978) Monoamine oxidase A and B: A useful concept? Biochem Pharmacol 27:97–101
Garrick NA, Redmond DE, Jr, Murphy DL (1979) Primate-rodent monoamine oxidase differences. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 351–359
Glover V, Sandler M, Owen F, Riley GJ (1977) Dopamine is a monoamine oxidase B substrate in man. Nature 265:80–81
Hagen P, Weiner N (1959) Enzymatic oxidation of pharmacologically active amines. Fed Proc 18:1005–1012
Hall DWR, Logan BW, Parsons GH (1969) Further studies on the inhibition of monoamine oxidase by M+B 9302 (clorgyline). Biochem Pharmacol 18:1447–1454
Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285–1297
Keane PE, Chanoine F, Strolin Benedetti M (1979) The effects of specific type A and B MAO inhibitors on reserpine-induced changes in brain dopamine and serum prolactin levels in the rat. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 341–346
Kinemuchi H, Wakui Y, Toyoshima Y, Hayashi N, Kamijo K (1979) β-Phenylethylamine (PEA), a concentration-dependent preferential substrate for multiple forms of MAO. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 205–212
Koenig JFR, Klippel RA: (1963) The rat brain. A stereotaxic atlas of the forebrain and lower parts of the brain stem. Baltimore: Williams and Wilkins
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Major LF, Murphy DL, Lipper S, Gordon E (1979) Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine and serotonin in human cerebrospinal fluid. J Neurochem 32:229–231
Murphy DL (1978) Substrate-selective monoamine oxidases: Inhibitor, tissue, species and functional differences. Biochem Pharmacol 27:1889–1893
Murphy DL, Donnelly CH, Richelson E (1976) Substrate and inhibitor-related characteristics of monoamine oxidase in C6 rat glial cells. J Neurochem 26:1231–1235
Murphy DL, Lipper S, Campbell IC, Major LF, Slater SL, Buchsbaum MS (1979) Comparative studies of MAO-A and MAO-B inhibitors in man. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 457–475
Murphy DL, Redmond DE, Jr, Garrick N, Baulu J (1979) Brain region differences and some characteristics of monoamine oxidase type A and B activities in the vervet monkey. Neurochem Res 4:53–62
Oommen A, Balasubramanian AS (1977) Studies on the monoamine oxidase of monkey brain. J Neurochem 28:645–654
Owen F, Cross AJ, Lofthouse R, Glover V (1979) Distribution and inhibition characteristics of human brain monoamine oxidase. Biochem Pharmacol 28:1077–1080
Robinson DS, Lovenberg W, Keiser H, Sjoerdsma J (1968) Effects of drugs on human blood platelet and plasma amine oxidase activity in vitro and in vivo. Biochem Pharmacol 17:109–119
Roth JA, Feor K (1978) Deamination of dopamine and its 3-0-methylated derivative by human brain monoamine oxidase. Biochem Pharmacol 27:1606–1608
Squires RF (1972) Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: A comparison of eight mammalian species. Adv Biochem Psychopharmacol 5:355–370
Suzuki O, Katsumata Y, Oya M (1979) Characterization of some biogenic monoamines as substrates for type A and type B monoamine oxidase. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 197–204
Waldmeier PC, Delini-Stula A, Maitre L (1976) Preferential deamination of dopamine by an A type monoamine oxidase in rat brain. Naunyn-Schmiedeberg's Arch Pharmacol 292:9–14
White HL, Glassman AT (1977) Multiple binding sites of human brain and liver monoamine oxidase: Substrate specificities, selective inhibitions, and attempts to separate enzyme forms. J Neurochem 29:987–997
Yang H-Y T, Neff NH (1974) The monoamine oxidases of brain: Selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther 189:733–740
Youdim MBH, Riederer P, Birkmayer W, Mendlewicz J (1979) The functional activity of monoamine oxidase: The use of deprenyl in the treatment of Parkinson's disease and depressive illness. In: Singer TP, Von Korff RW, Murphy DL (eds) Monoamine oxidase: Structure, function and altered functions. Academic Press, New York, pp 477–496
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garrick, N.A., Murphy, D.L. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology 72, 27–33 (1980). https://doi.org/10.1007/BF00433804
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00433804